[
  {
    "ts": "2025-11-20T12:25:06+00:00",
    "headline": "Regeneron’s Eylea franchise boosted by pair of FDA approvals",
    "summary": "Eylea HD’s new RVO indication and a monthly dosing option will notch up the rivalry with Roche’s Vabysmo.",
    "url": "https://www.pharmaceutical-technology.com/news/regenerons-eylea-franchise-boosted-by-pair-of-fda-approvals/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "02f108e4-8404-3b3f-a25f-5a1a382070db",
      "content": {
        "id": "02f108e4-8404-3b3f-a25f-5a1a382070db",
        "contentType": "STORY",
        "title": "Regeneron’s Eylea franchise boosted by pair of FDA approvals",
        "description": "",
        "summary": "Eylea HD’s new RVO indication and a monthly dosing option will notch up the rivalry with Roche’s Vabysmo.",
        "pubDate": "2025-11-20T12:25:06Z",
        "displayTime": "2025-11-20T12:25:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/c3f05e07237ca9c369702d71e007f3bf",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G62QEtIF546bCWwYWypliw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/c3f05e07237ca9c369702d71e007f3bf.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s.nQ_ljtJuO6NZl17KGshQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/c3f05e07237ca9c369702d71e007f3bf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/regenerons-eylea-franchise-boosted-by-pair-of-fda-approvals/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-eylea-franchise-boosted-pair-122506595.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "ROG.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T15:34:13+00:00",
    "headline": "Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron",
    "summary": "↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares climbed 6%. ↗️ Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.",
    "url": "https://www.wsj.com/livecoverage/jobs-report-bls-september-stock-market-today-11-20-2025/card/stocks-to-watch-thursday-nvidia-amd-walmart-6oQvCREXi20dufYs21ry?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "c12dd2a4-ebaa-3cb1-a576-7aea5d2a6219",
      "content": {
        "id": "c12dd2a4-ebaa-3cb1-a576-7aea5d2a6219",
        "contentType": "STORY",
        "title": "Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron",
        "description": "",
        "summary": "↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares climbed 6%. ↗️ Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.",
        "pubDate": "2025-11-20T15:34:13Z",
        "displayTime": "2025-11-20T15:34:13Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/c12dd2a4-ebaa-3cb1-a576-7aea5d2a6219/stocks-to-watch-thursday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/2fe33970c8bdf092fb792f6e87e5802b",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M7_rA.nIZVw1Y9F9FSCaKw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/2fe33970c8bdf092fb792f6e87e5802b.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jRFdkZ8IsIDLovdMAGDDFw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/2fe33970c8bdf092fb792f6e87e5802b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/jobs-report-bls-september-stock-market-today-11-20-2025/card/stocks-to-watch-thursday-nvidia-amd-walmart-6oQvCREXi20dufYs21ry?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "BBWI"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:19:00+00:00",
    "headline": "REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD",
    "summary": "Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.",
    "url": "https://finance.yahoo.com/news/regn-gets-ec-nod-libtayo-141900472.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "afa6dcd5-23c3-38f1-887c-157e6904f2df",
      "content": {
        "id": "afa6dcd5-23c3-38f1-887c-157e6904f2df",
        "contentType": "STORY",
        "title": "REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD",
        "description": "",
        "summary": "Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.",
        "pubDate": "2025-11-20T14:19:00Z",
        "displayTime": "2025-11-20T14:19:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/57.Lfvcoa8N_9pHFAUTShA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/39hBnd4FwGlouiqapgQKxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regn-gets-ec-nod-libtayo-141900472.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regn-gets-ec-nod-libtayo-141900472.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "BAYZF"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T11:36:00+00:00",
    "headline": "With new approvals, Regeneron’s higher-dose Eylea gets more competitive",
    "summary": "Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.",
    "url": "https://www.biopharmadive.com/news/regeneron-eylea-hd-fda-approvals-eye-market-roche/806053/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "a83ab303-47b4-3521-94bc-4cc54c2de120",
      "content": {
        "id": "a83ab303-47b4-3521-94bc-4cc54c2de120",
        "contentType": "STORY",
        "title": "With new approvals, Regeneron’s higher-dose Eylea gets more competitive",
        "description": "",
        "summary": "Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.",
        "pubDate": "2025-11-20T11:36:00Z",
        "displayTime": "2025-11-20T11:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/6c457f09b31ec38cbcee1b86f4fd559e",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "FDA headquarters in White Oak, Maryland",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/S1HyqXOsMPbVH30jua67bw--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/6c457f09b31ec38cbcee1b86f4fd559e.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/92iy8Wi9RZeX2J..w0ijaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/6c457f09b31ec38cbcee1b86f4fd559e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/regeneron-eylea-hd-fda-approvals-eye-market-roche/806053/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/approvals-regeneron-higher-dose-eylea-113600137.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]